Advanced Search

Technical Analysis for PRTC - PureTech Health plc

Grade Last Price % Change Price Change
grade F 39.5 2.30% 0.89
PRTC closed up 2.3 percent on Friday, November 27, 2020, on 24 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical PRTC trend table...
Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Gapped Down Weakness 2.30%
Hot IPO Pullback Bullish Swing Setup 1.72%
Down 3 Days in a Row Weakness 1.72%
Hot IPO Pullback Bullish Swing Setup -0.77%
Multiple of Ten Bearish Other -0.77%
Outside Day Range Expansion -0.77%
Hot IPO Pullback Bullish Swing Setup -1.25%
Narrow Range Bar Range Contraction -1.25%
Older End-of-Day Signals for PRTC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% 6 days ago
Fell Below Previous Day's Low 6 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators Basic chart:

Profile

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Biotechnology Biopharmaceutical Health Life Sciences Pharmaceutical Industry Immunology Medication Health Sciences Schizophrenia Specialty Drugs Monoclonal Antibody Central Nervous System Disorders Hematologic Malignancies Alzheimer's Chronic Diseases Immune Mediated Diseases Inflammatory Disorders Cognitive Dysfunction Kar Xt Lymphedema Parkinson Parkinson's Diseases

Is PRTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Nov 24 PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
Nov 24 Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors
Nov 18 PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study
See more PRTC news...

Indicators

Indicator Value
52 Week High 41.81
52 Week Low 33.0
Average Volume 1,695
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Fundamentals Value
Market Cap 1.13 Billion
Num Shares 28.6 Million
EPS
Price-to-Sales 93.65
Price-to-Book 1.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.50
Resistance 3 (R3) 39.50 39.50 39.50
Resistance 2 (R2) 39.50 39.50 39.50 39.50
Resistance 1 (R1) 39.50 39.50 39.50 39.50 39.50
Pivot Point 39.50 39.50 39.50 39.50 39.50
Support 1 (S1) 39.50 39.50 39.50 39.50 39.50
Support 2 (S2) 39.50 39.50 39.50 39.50
Support 3 (S3) 39.50 39.50 39.50
Support 4 (S4) 39.50